Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL AND PROGESTERONE versus LEVONORGESTREL.
Head-to-head clinical analysis: ESTRADIOL AND PROGESTERONE versus LEVONORGESTREL.
ESTRADIOL AND PROGESTERONE vs LEVONORGESTREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol binds to and activates estrogen receptors (ERα and ERβ) in target tissues, modulating gene transcription and non-genomic signaling pathways. Progesterone binds to the progesterone receptor (PR), regulating endometrial differentiation and inhibiting estrogen-induced mitogenesis.
Synthetic progestin that suppresses gonadotropin release (GnRH, LH, FSH) via negative feedback on the hypothalamic-pituitary-ovarian axis; inhibits ovulation, thickens cervical mucus, and alters endometrial lining.
Estradiol 1 mg orally once daily plus progesterone 200 mg orally once daily for 12-14 days per cycle (or continuous combined regimen: estradiol 0.5-1 mg orally once daily plus progesterone 100 mg orally once daily). For hormone replacement therapy: estradiol 0.5-2 mg orally once daily continuously; medroxyprogesterone acetate 2.5-5 mg orally once daily for 12-14 days per month (if progesterone used). Menopausal vasomotor symptoms: estradiol 0.5-1 mg orally once daily; if uterus intact, add progesterone 200 mg orally once daily for 12 days per month or 100 mg orally once daily continuously. Osteoporosis prevention: estradiol 0.5 mg orally once daily; progesterone as above. Topical: estradiol transdermal system 0.025-0.1 mg/day applied once weekly; progesterone vaginal gel 4% or 8% inserted once daily. Dose titrated to minimum effective. Maximum daily estradiol dose: 2 mg orally.
For emergency contraception: 1.5 mg orally as a single dose or 0.75 mg orally 12 hours apart. For hormonal contraception: 0.03 mg to 0.05 mg orally once daily in combined oral contraceptives; for progestin-only oral contraceptive (mini-pill): 0.03 mg orally once daily. For intrauterine system (IUD): 52 mg intrauterine device inserted for up to 5 years.
Clinical Note
moderateLevonorgestrel + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Levonorgestrel."
Clinical Note
moderateLevonorgestrel + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Levonorgestrel."
Clinical Note
moderateLevonorgestrel + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Levonorgestrel."
Clinical Note
moderateLevonorgestrel + Fluconazole
None Documented
None Documented
Estradiol: terminal half-life 13-16 hours; steady-state achieved after 2-3 days with transdermal administration. Progesterone: terminal half-life 16-18 hours; micronized oral form has a half-life of approximately 17 hours.
Terminal half-life: 24-30 hours (range 11-45 hours). This prolonged half-life supports once-daily or extended-cycle dosing in contraceptive formulations.
Estradiol is primarily excreted as glucuronide and sulfate conjugates in urine (approximately 80%) and feces (approximately 20%). Progesterone is excreted mainly as pregnanediol glucuronide in urine (50-60%) and lesser amounts in feces.
Renal: 45-60% (metabolites), Fecal: 32-45% (unchanged and metabolites). Biliary excretion contributes to fecal elimination.
Category D/X
Category C
Progestin
Progestin
"The metabolism of Fluconazole can be decreased when combined with Levonorgestrel."